Log in
Enquire now

List of SBIR/STTR awards granted to GEM Pharmaceuticals

List of SBIR/STTR awards granted to GEM Pharmaceuticals
List of SBIR/STTR awards granted to IRGLARE, LLC
List of SBIR/STTR awards granted to VISTA PHOTONICS, INC.
List of SBIR/STTR awards granted to IRIS MEDIA INC
List of Alcor Micro patents
Investors in Binance
where
SBIR/STTR Award Recipient
is
‌
GEM Pharmaceuticals
Name
Description
SBIR/STTR Award Recipient
Government Agency
Government Branch
Award Type
Contract Number (US Government)
Award Phase
Award Amount (USD)
Date Awarded
Official Website
‌
GEM Pharmaceuticals SBIR Phase I Award,

A SBIR Phase I contract was awarded to GEM Pharmaceuticals for $149,052.0 USD from the U.S. Department of Health & Human Services.

‌
GEM Pharmaceuticals
SBIR
1R41AR052955-01
Phase I
149,052
sbir.gov/node/1068357
‌
GEM Pharmaceuticals STTR Phase I Award,

A STTR Phase I contract was awarded to GEM Pharmaceuticals for $195,590.0 USD from the U.S. Department of Health & Human Services.

‌
GEM Pharmaceuticals
STTR
1R41HL076924-01
Phase I
195,590
sbir.gov/content/cardiac-interactions-new-adriamycin-analogs-and-taxol-0
‌
GEM Pharmaceuticals SBIR Phase I Award,

A SBIR Phase I contract was awarded to GEM Pharmaceuticals for $195,590.0 USD from the U.S. Department of Health & Human Services.

‌
GEM Pharmaceuticals
SBIR
1R41HL076924-01
Phase I
195,590
sbir.gov/node/1066551
‌
GEM Pharmaceuticals STTR Phase II Award,

A STTR Phase II contract was awarded to GEM Pharmaceuticals for $557,528.0 USD from the U.S. Department of Health & Human Services.

‌
GEM Pharmaceuticals
STTR
2R42HL064986-02
Phase II
557,528
sbir.gov/content/novel-doxorubicin-analogscardiac-and-cytotoxic-effects-0
‌
GEM Pharmaceuticals STTR Phase I Award,

A STTR Phase I contract was awarded to GEM Pharmaceuticals from the U.S. Department of Health & Human Services.

‌
GEM Pharmaceuticals
STTR
2R42HL064986-02
Phase I
0
sbir.gov/content/novel-doxorubicin-analogscardiac-and-cytotoxic-effects-2
‌
GEM Pharmaceuticals STTR Phase I Award,

A STTR Phase I contract was awarded to GEM Pharmaceuticals for $149,052.0 USD from the U.S. Department of Health & Human Services.

‌
GEM Pharmaceuticals
STTR
1R41AR052955-01
Phase I
149,052
sbir.gov/content/utility-novel-anthracycline-analog-psoriasis-0
6 results
0 selected
6 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us